OBJECTIVE: We studied changes in bone mineral density (BMD) and bone turnover after initiation of combination antiretroviral therapy (cART) and the contribution of zidovudine/lamivudine (ZDV/3TC) in particular. DESIGN: Randomized clinical trial comparing lopinavir/ritonavir(LPV/r) + ZDV/3TC with LPV/r + nevirapine (NVP) in 50 cART-naive men. METHODS:Dual energy X-ray absorptiometry (DXA) and quantitative computed tomography scans (QCT) were performed at baseline and 3, 12, and 24 months after cART initiation. Serum 25-hydroxy-vitamin D3, parathyroid hormone (PTH), osteocalcin, and urine deoxypyridinoline (DPD)/creatinine ratio were measured. RESULTS:BMD decreased rapidly in both femoral neck and lumbar spine after cART initiation. BMD loss during 24 months measured by DXA, but not by QCT, was greater in the ZDV/3TC/LPV/r group compared to the NVP/LPV/r group [femoral neck: -6.3% +/- 1.0% (P < 0.0001) compared to -2.3% +/- 0.9% (P = 0.01), between-group P = 0.0006); lumbar spine: -5.1% +/- 0.8% (P < 0.0001) compared to -2.6% +/- 0.7% (P = 0.0006), between-group P = 0.07]. Osteocalcin [+1.60 +/- 0.32 (P < 0.0001) and +1.81 +/- 0.29 (P < 0.0001) nmol/l] and the urine DPD/creatinine ratio [+1.35 +/- 0.44 (P = 0.0029) and +1.19 +/- 0.38 nmol/mmol (P = 0.0024)] increased in both groups over 24 months, with no significant difference between groups. PTH increased to a greater degree in the NVP/LPV/r group [+2.0 +/- 0.31 pmol/l (P < 0.0001)] compared to [+0.81 +/- 0.33 pmol/l (P = 0.021) in the ZDV/3TC/LPV/r group]. CONCLUSION:BMD in both femoral neck and lumbar spine decreased rapidly after initiation of cART, in parallel to an increase in bone turnover. The greater bone loss in the ZDV/3TC/LPV/r group compared to the NVP/LPV/r group suggests that ZDV/3TC contributes to this process. The PTH increase does not explain this greater bone loss.
RCT Entities:
OBJECTIVE: We studied changes in bone mineral density (BMD) and bone turnover after initiation of combination antiretroviral therapy (cART) and the contribution of zidovudine/lamivudine (ZDV/3TC) in particular. DESIGN: Randomized clinical trial comparing lopinavir/ritonavir(LPV/r) + ZDV/3TC with LPV/r + nevirapine (NVP) in 50 cART-naive men. METHODS: Dual energy X-ray absorptiometry (DXA) and quantitative computed tomography scans (QCT) were performed at baseline and 3, 12, and 24 months after cART initiation. Serum 25-hydroxy-vitamin D3, parathyroid hormone (PTH), osteocalcin, and urine deoxypyridinoline (DPD)/creatinine ratio were measured. RESULTS: BMD decreased rapidly in both femoral neck and lumbar spine after cART initiation. BMD loss during 24 months measured by DXA, but not by QCT, was greater in the ZDV/3TC/LPV/r group compared to the NVP/LPV/r group [femoral neck: -6.3% +/- 1.0% (P < 0.0001) compared to -2.3% +/- 0.9% (P = 0.01), between-group P = 0.0006); lumbar spine: -5.1% +/- 0.8% (P < 0.0001) compared to -2.6% +/- 0.7% (P = 0.0006), between-group P = 0.07]. Osteocalcin [+1.60 +/- 0.32 (P < 0.0001) and +1.81 +/- 0.29 (P < 0.0001) nmol/l] and the urine DPD/creatinine ratio [+1.35 +/- 0.44 (P = 0.0029) and +1.19 +/- 0.38 nmol/mmol (P = 0.0024)] increased in both groups over 24 months, with no significant difference between groups. PTH increased to a greater degree in the NVP/LPV/r group [+2.0 +/- 0.31 pmol/l (P < 0.0001)] compared to [+0.81 +/- 0.33 pmol/l (P = 0.021) in the ZDV/3TC/LPV/r group]. CONCLUSION: BMD in both femoral neck and lumbar spine decreased rapidly after initiation of cART, in parallel to an increase in bone turnover. The greater bone loss in the ZDV/3TC/LPV/r group compared to the NVP/LPV/r group suggests that ZDV/3TC contributes to this process. The PTH increase does not explain this greater bone loss.
Authors: Adolf Pfefferbaum; David A Rogosa; Margaret J Rosenbloom; Weiwei Chu; Stephanie A Sassoon; Carol A Kemper; Stanley Deresinski; Torsten Rohlfing; Natalie M Zahr; Edith V Sullivan Journal: Neurobiol Aging Date: 2014-01-13 Impact factor: 4.673
Authors: Linda A DiMeglio; JiaJia Wang; George K Siberry; Tracie L Miller; Mitchell E Geffner; Rohan Hazra; William Borkowsky; Janet S Chen; Laurie Dooley; Kunjal Patel; Russell B van Dyke; Roger A Fielding; Yared Gurmu; Denise L Jacobson Journal: AIDS Date: 2013-01-14 Impact factor: 4.177
Authors: Philip M Grant; Virginia Sheikh; Rebecca DerSimonian; Adam Rupert; Gregg Roby; Alice Pau; Michael C Sneller; Sheryl-Vi Rico; Todd T Brown; Irini Sereti Journal: AIDS Res Hum Retroviruses Date: 2015-05-21 Impact factor: 2.205
Authors: Vincent Lo Re; Kenneth Lynn; Emily R Stumm; Jin Long; Melissa S Nezamzadeh; Joshua F Baker; Andrew N Hoofnagle; Angela J Kapalko; Karam Mounzer; Babette S Zemel; Pablo Tebas; Jay R Kostman; Mary B Leonard Journal: J Infect Dis Date: 2015-03-09 Impact factor: 5.226
Authors: T Porcelli; D Gotti; A Cristiano; F Maffezzoni; G Mazziotti; E Focà; F Castelli; A Giustina; E Quiros-Roldan Journal: Osteoporos Int Date: 2014-07-24 Impact factor: 4.507